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Abstract
Zygomycosis is an important emerging fungal infection, associated with high morbidity and mortality. The Working Group on Zygomy-
cosis of the European Confederation of Medical Mycology (ECMM) prospectively collected cases of proven and probable zygomycosis
in 13 European countries occurring between 2005 and 2007. Cases were recorded by a standardized case report form, entered into an
electronic database and analysed descriptively and by logistic regression analysis. During the study period, 230 cases fulﬁlled pre-set cri-
teria for eligibility. The median age of the patients was 50 years (range, 1 month to 87 years); 60% were men. Underlying conditions
included haematological malignancies (44%), trauma (15%), haematopoietic stem cell transplantation (9%) and diabetes mellitus (9%).
The most common manifestations of zygomycosis were pulmonary (30%), rhinocerebral (27%), soft tissue (26%) and disseminated dis-
ease (15%). Diagnosis was made by both histology and culture in 108 cases (44%). Among 172 cases with cultures, Rhizopus spp. (34%),
Mucor spp. (19%) and Lichtheimia (formerly Absidia) spp. (19%) were most commonly identiﬁed. Thirty-nine per cent of patients received
amphotericin B formulations, 7% posaconazole and 21% received both agents; 15% of patients received no antifungal therapy. Total
mortality in the entire cohort was 47%. On multivariate analysis, factors associated with survival were trauma as an underlying condition
(p 0.019), treatment with amphotericin B (p 0.006) and surgery (p <0.001); factors associated with death were higher age (p 0.005) and
the administration of caspofungin prior to diagnosis (p 0.011). In conclusion, zygomycosis remains a highly lethal disease. Administration
of amphotericin B and surgery, where feasible, signiﬁcantly improve survival.
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Introduction
Although often described as a rare fungal infection, zygo-
mycosis (mucormycosis) appears to be increasing in fre-
quency [1]. It mainly affects immunocompromized patients,
such as those with haematological malignancies, recipients
of haematopoietic stem cell (HSCT) [2] or solid organ
transplants (SOT) [3], patients with diabetes mellitus and
ketoacidosis [4,5], and infants with prematurity [6]. Zygo-
mycosis may also affect immunocompetent patients with
trauma or burns, or patients with elevated serum levels of
iron under treatment with deferroxamine. The increased
frequency of this infection is attributed to the rising preva-
lence of diabetes mellitus, as well as to the increased use
of immunosuppressive treatments. The introduction of
newer antifungals, in particular voriconazole, has also been
suggested to play a role in the increased incidence of
zygomycosis [7]. Due to the relative rarity of the disease
it is difﬁcult to perform stringent epidemiological studies
to estimate its exact incidence. Most of the available data
stem from case series and pertain to haematological
patients [8] or to patients who have undergone transplan-
tation [9]. An active population-based surveillance in the
Bay Area of San Francisco, USA, was published in 1998
[10].
While mortality approached 100% in the older literature
depending on the patients’ underlying disease and the type of
zygomycosis [11], it has been reduced since amphotericin B
has become available [12]. Since then, however, it has
remained essentially unchanged. Nevertheless, with the avail-
ability of the less toxic lipid formulations, survival rates of up
to 85% have recently been reported in select patient popula-
tions [13,14].
Taking into consideration the challenges related to epide-
miology, treatment and outcome of zygomycosis, a working
group on zygomycosis was formed by the European Confed-
eration of Medical Mycology (ECMM). The aim of the group
was to analyse the clinical characteristics, microbiology,
treatment practices and outcome of zygomycosis in Europe
through a voluntary case registry. We present here the
results of the ﬁrst 3 years (2005–2007) of this effort.
Patients and Methods
Study design
In each participating European country, a national coordina-
tor was appointed, who prospectively collected zygomycosis
cases, recorded by the treating physicians in standardized
case report forms (CRFs), which were then sent either by e-
mail or fax to the general study coordinator. The national
coordinators were all experts in the ﬁeld of zygomycosis and
in most cases were appointed by the respective national
Mycology Societies. The participating hospitals were selected
by the national coordinator on the basis of their capacity to
document all episodes of zygomycosis occurring during the
study period.
Mucorales isolates were initially identiﬁed at the partici-
pating institutions by the routine methods used in each labo-
ratory. Molecular identiﬁcation was then performed either at
a national centre (Institut Pasteur in Paris, Medical University
in Innsbruck, etc.) or the isolates were sent to a central lab-
oratory in Spain (National Centre for Mycology, Madrid) for
sequencing. Furthermore, coordinators were informed that
they could send parafﬁn-embedded tissue for PCR identiﬁca-
tion to a central laboratory in Germany [15].
In order to be included as a case in the registry, sufﬁ-
cient information regarding diagnosis, predisposing factors
and clinical presentation had to be provided. The CRFs
were reviewed by the principal investigators (GP and AS)
and queries were sent to the national coordinators in
order to complete missing data. After completing the data-
base, a data review committee examined all the data. The
study was approved by the Ethics Committee of the Uni-
versity of Athens ‘Laikon General Hospital’, in Athens,
Greece, the institution of the principal investigators. In addi-
tion, approval was also obtained from local ethics commit-
tees of all collaborating countries according to local
regulations.
Deﬁnitions
For the classiﬁcation of each case as proven or probable, the
revised deﬁnitions of invasive fungal disease of the European
Organization for Research and Treatment of Cancer/Mycosis
Study Group (EORTC/MSG) were used [16], with the fol-
lowing modiﬁcation: if the diagnosis was made by histology
and there was PCR testing on tissue positive for zygomyce-
tes (from the central laboratory described above), the case
was classiﬁed as proven zygomycosis, even if there were no
cultures available. In addition, diabetes mellitus was also
included in the host criteria.
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Diagnosis by histology was made if large, non-septate
hyphae were reported. The sites of infection were classiﬁed as
recently described by Roden et al. [4]. Mortality was assessed
as all-cause mortality during the course of zygomycosis.
Statistical analysis
Statistical analyses were conducted using SPSS v.16. Differences
between the qualitative variables in two or more groups
were analysed by a chi-square test. A two-sided p value of
<0.05 was considered signiﬁcant. For the estimation of pre-
dictors of outcome the following method was used. Univari-
ate analysis was performed using logistic regression for each
variable separately. Variables entered into univariate analysis
included age, sex, underlying diseases, treatment with corti-
costeroids, immunosuppressives or antifungals prior to the
diagnosis of zygomycosis, sites of infection and types of treat-
ment. The variables for which a statistically signiﬁcant rela-
tionship was shown (p <0.05) were used to construct a new
multivariate model using the logistic regression approach. The
multivariate results presented are those from the most parsi-
monious model, including only the selected covariates.
Results
During the period between January 2005 and December
2007, 15 countries submitted 237 cases to the study, of
which 230 were eligible for inclusion: Italy (60 cases), Greece
(36), Germany (35), Switzerland (22), France (21), Belgium
(16), Austria (12), Spain (9), Russia (6), Norway (5), Finland
(2), Turkey (2), Czech Republic (2), Netherlands (1), UK (1).
Seven cases were excluded because the data provided were
not sufﬁcient to classify them either as proven or as proba-
ble zygomycosis. The median age of the patients was
50 years, ranging from 1 month to 87 years; 60% of the
patients were of male gender. Seventeen patients were youn-
ger than 14 years and three were £1 year old.
Underlying conditions
The patients’ underlying conditions are listed in Table 1. In
the month prior to diagnosis of zygomycosis, 106 (46%)
patients received corticosteroids and 101 (44%) received
other immunosuppressive medications (cyclosporine, myco-
phenolate-mofetil, tacrolimus, everolimus, methotrexate,
cyclophosphamide, daunorubicin, vincristin, cytarabin, chlor-
ambucil, ﬂudarabine or novantrone). One hundred and ten
patients (48%) received antifungals in the same period: ﬂuco-
nazole (19%), itraconazole (3%) and posaconazole (1%) as
prophylaxis, and voriconazole (19%), caspofungin (13%) and
amphotericin B (13%) as empirical treatment.
Eight patients with haematological malignancies also had
diabetes mellitus, secondary to steroid use in most cases,
while in one case, the patient had acute lymphoblastic leu-
kaemia and AIDS.
Diabetes was the sole predisposing factor in 21 (9%)
patients. In another 18 (8%), diabetes was combined with
other underlying conditions, such as malignancy or trauma.
Of the 39 cases with trauma, 18 had surgical trauma and 4
had various underlying diseases (non-Hodgkin lymphoma,
Ewing sarcoma, solid organ transplantation and diabetes).
The remaining 16 patients were immunocompetent and
trauma was the sole predisposing factor for zygomycosis. In
another two patients no predisposing factor was found.
Thus, in total, there were 18 (8%) patients that were consid-
ered immunocompetent.
The majority of children in the <14 year age group had an
underlying haematological malignancy (n = 8, 47%), while the
rest had trauma (2), solid organ transplantation (2), alloge-
neic bone marrow transplantation (1), osteosarcoma (1),
type I diabetes mellitus (1), aplastic anaemia (1) and Pear-
son’s syndrome (1). Two of the three infants had undergone
solid organ transplantation and one had Pearson’s syndrome.
Sites of infection
The types of infection by site are shown in Table 2. The dis-
tribution of reported sites in children was similar. Statistical
TABLE 1. Underlying conditions predisposing to zygomyco-
sis and mortalitya
Underlying condition
Number of
patients (%)
Number of patients
who died (%)b
Haematological malignanciesc 102 (44) 49/95 (52)
Acute myeloid leukaemia 49/102 (48)
Acute lymphoblastic leukaemia 22/102 (22)
Non-Hodgkin lymphoma 11/102 (11)
Myelodysplastic syndrome 6/102 (6)
Other 12/102 (12)
Haematopoietic stem cell
transplantationd
21 (9) 13/17 (76)
Other malignancies 11 (5) 5/9 (56)
Solid organ transplantation 10 (4) 5/10 (50)
Diabetes mellitus 39 (17) 18/33 (55)
Trauma 39 (17) 13/32 (41)
Burn 7 (3) 2/6 (33)
HIV/AIDS 4 (2) 0/3 (0)
Aplastic anaemia 4 (2) 1/4 (25)
Othere 9 (4) 4/9 (44)
aNineteen patients (8%) had more than one underlying disease, so the total is
more than 100%.
bThe number of patients is smaller in this column than the number in the left
column because some data regarding outcome were missing.
cThe patients who underwent transplantation are not included in this group.
dHaematopoietic stem cell transplantations (n = 21) were allogeneic, except for
two cases, for whom the treating physicians stated that the patients had under-
gone ‘bone marrow transplantation’ without further clariﬁcation.
eOne patient had neutropenia due to treatment for psoriatic arthritis, one was
receiving deferroxamine, and the other seven were receiving corticosteroids for
various reasons (two for chronic obstructive pulmonary disease, two for
Wegener’s granulomatosis, one for panarteritis nodosa, one for Goodpasture’s
syndrome and one for rheumatoid arthritis)
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analysis (comparison of frequencies of sites of infection for
every underlying disease) showed a signiﬁcant relationship
between underlying disease and site of infection (Fig. 1). Hae-
matological malignancy correlated with pulmonary disease: of
68 patients with pulmonary zygomycosis, 35 had a haemato-
logical malignancy (51.47%). Vice versa, diabetes correlated
with rhinocerebral disease: of the 21 patients with rhinoce-
rebral disease, 11 had diabetes (52.38%; p <0.001).
Diagnosis
In 10 (4%) cases the diagnosis of zygomycosis was made
post-mortem, and in a further six cases it was diagnosed
ante-mortem and conﬁrmed at autopsy. The various meth-
ods of diagnosis are presented in Table 3. Results of cultures
were available in 172 patients (74%; Table 4). These results
were conﬁrmed by molecular sequencing methods in only
40% of cases. In the 58 patients with no culture results,
either no material was sent for culture, or cultures were
performed but were negative. Diagnosis was made by both
histology and culture in 108 cases (44%). These 108 cases
were classiﬁed as proven according to the modiﬁed EORTC/
MSG criteria. Another four cases were classiﬁed as proven
because the diagnosis was made by histology and PCR. The
remaining 118 cases were classiﬁed as probable zygomycosis.
The 35 patients who were diagnosed as having probable
zygomycosis based only on positive cultures, had underlying
malignancies or diabetes mellitus and a clinical picture of pul-
monary or rhinocerebral disease.
Treatment and outcome
Various approaches to treatment were used, including anti-
fungal chemotherapy and surgery (Table 5). Of the 230
patients included in the study, data regarding antifungal medi-
cation were available for 225 patients. Thirty-three patients
received no antifungal medication, either because the diagno-
sis was made at post-mortem (in 10), or during the last 24 h
prior to death (in 14), or because only surgical treatment
was performed (in 9). Zygomycosis was successfully cured by
the sole use of surgery in two patients who were burn vic-
tims with cutaneous disease, in two patients who had maxil-
lary sinusitis but were otherwise immunocompetent and in
one patient who had a brain abscess.
Of the 192 patients who received antifungal medication,
167 (87%) received amphotericin B as ﬁrst line treatment.
The formulation used most frequently was liposomal ampho-
tericin B (130/167 patients, 78%). In 10 (6%) cases the for-
mulation of amphotericin B used was unspeciﬁed, in 21
(13%) it was amphotericin B deoxycholate and in 7 (4%) it
was amphotericin B lipid complex. Amphotericin B was given
either alone or in combination with other antifungal agents
(Table 6). In some cases where administration of amphoteri-
cin B was followed by posaconazole, there were reports of
lengths of treatment of as long as 603 days. In the group of
patients who received liposomal amphotericin B as the only
antifungal medication and were cured, the median duration
of treatment was 55 days (range, 14–169 days) and the med-
ian daily dose was 5 mg/kg (range, 3–10 mg/kg).
Total mortality was 47%. Mortality in the children’s group
was 27%. Mortality rates were variable depending on the
underlying diseases (Table 1), on the site of infection
(Table 2), and on treatment (Tables 5,6). Table 7 shows the
risk factors affecting mortality found to be signiﬁcant on uni-
variate and multivariate analysis. As shown on multivariate
analysis, age was an independent predictor of death. Increase
of age by 1 year augments the risk of death by 3%. The
same statistical model showed that patients who developed
zygomycosis as a result of trauma had an 86% smaller proba-
bility of death compared with patients with haematological
TABLE 2. Sites of infection and mortality among 230
patients. The outcome was evaluated in 200 patients, of
whom 94 (47%) died
Type of infection
by site
Number of
patients (%)
Number of patients
who died (%)a
Sinus
Overall 62/230 (27) 28/58 (48)
Sinusitis 27/62 9/26 (35)
Sino-orbital 9/62 5/8 (63)
Rhinocerebral 26/62 14/24 (58)
Pulmonary
Overall 68/230 (30) 33/59 (56)
Localizedb 65/68 (96) 30/56 (54)
Deep extension 3/68 (4) 3/3 (100)
Cutaneous
Overall 59/230 (26) 13/47 (28)
Localizedc 36/59 8/30 (27)
Deep extension 23/59 5/17 (29)
Cerebral, isolatedd 5/230 (2) 1/5 (20)
Disseminatede 34/230 (15) 18/31 (58)
Lung 31/34 15/28 (54)
Sinus 11/34 6/10 (60)
Soft tissue 7/34 3/7 (43)
CNSf 18/34 13/17 (76)
Liver 6/34 3/5 (60)
Kidney 5/34 2/4 (50)
Other organ 8/34 7/8 (88)
Heart 1/230 1/1 (100)
Liver 1/230 0/1 (0)
aThe total number of cases for each site is smaller than the one in the second
column, because data about outcome were missing in some cases and were not
included.
bLung infection was characterized as localized when it was only in the lung tis-
sue and with deep extension when it extended to adjacent tissues, such as the
pleura, the heart, etc.
cCutaneous infection was characterized as localized when it did not extend to
underlying tissues (muscle or bone), in which case it was characterized as having
deep extension.
dThe total number of cases with involvement of the brain, including isolated
cerebral, rhinocerebral and disseminated disease, was 49/230 (21%).
eVarious combinations of involved organs were reported. The most common
combination was sino-pulmonary zygomycosis (10/34, 29%).
fFive of the 18 cases of CNS involvement in disseminated disease were rhinoce-
rebral zygomycosis with dissemination.
gSino-orbital refers to cases involving the sinus and orbit, without extension to
the brain.
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malignancies. Amphotericin B, either alone or with posaco-
nazole or with posaconazole and other antifungals (in combi-
nation or sequentially), signiﬁcantly decreased the risk of
death. Finally, surgical treatment decreased the risk of death
by 79%. Regarding administration of antifungals prior to the
diagnosis of zygomycosis, voriconazole and caspofungin were
found to be risk factors on univariate analysis, but only ca-
spofungin remained as an independent risk factor on multi-
variate analysis.
Discussion
Thus far, this is the largest and geographically most diverse
study on the contemporary epidemiology of zygomycosis in
Europe. While no conclusions regarding incidence rates are
feasible due to the absence of a denominator, several impor-
tant observations can be made that are helpful to better
understand the current evolution of the disease. The most
common underlying diseases were haematological malignan-
cies (n = 102, 44%), while diabetes was found in 39 patients
(17%). This is in contrast to the extensive literature compila-
tion by Roden et al. [4], who reported that malignancies con-
stituted 17% of all cases, whereas diabetes was the
underlying condition in 36% of 929 cases. This could be
explained by the fact that the number of immunocomprom-
ized patients has dramatically increased in recent decades. It
may also be partly due to the predominance of haematology
centres participating in the study. In the analysis of 41 cases
by Ruping et al. [17], malignancies were the predisposing fac-
tor in 63% of cases and diabetes in 17%, but in that study
also the majority of contributing investigators were haema-
tologists. It is not surprising that incidence rates are different
in each study, because there has been no deﬁned denomina-
tor in any of them, including the present one. Trauma was
found to be a predisposing factor in 17% of cases. Of note,
eight of the 18 cases (44%) with surgical trauma were sub-
mitted from the same centre and constituted an outbreak of
zygomycosis in a Greek hospital [18], thus signiﬁcantly inﬂu-
encing the percentage.
The most common sites of infection were the lungs, the
sinuses and the soft tissues. Pulmonary zygomycosis was
most common in patients with haematological malignancies,
TABLE 3. Laboratory methods used for the diagnosis of
zygomycosis
Diagnostic methods
Number of
patients (%)
Histology + culture + direct examination 69 (30)
Histology + culture 39 (17)
Histology + PCR15 4 (2)
Only histology 24 (10)
Only culture 35 (15)
Culture + direct examination 29 (13)
Histology + direct examination 16 (7)
Only direct examination 14 (6)
Pulmonary
34%
Rhinocerebral
15%SinusiƟs
13%
SoŌ Ɵssue
10%
Disseminated
27%
Liver
1%
SoŌ Ɵssues
89%
SinusiƟs
5%
Pulmonary
6%
Haematological malignancies (n = 102) 
No underlying disease (n = 18) 
Immunocompetent patients with trauma are included in the group 
Rhinocerebral
52%
SinusiƟs
10%
SoŌ Ɵssue
14%
Pulmonary
14%
Disseminated
10%
Diabetes (n = 21) 
FIG. 1. Sites of infections in relation to underlying disease. Infection localized to sinuses is termed ‘sinusitis’, while if it extends to the orbit or
the brain it is termed ‘‘rhinocerebral’’. Disseminated infection is deﬁned as infection involving at least two non-contiguous sites.
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and rhinocerebral disease in patients with diabetes (Fig. 1).
These associations have been reported in other studies
[4,17,19] and various pathogenetic mechanisms have been
proposed [4]. However, the exact pathogenesis leading to
the association between diabetes and rhinocerebral disease
is not clear [20].
The diagnosis of zygomycosis is difﬁcult, despite the avail-
ability of modern methods. As a result, 4% of all cases were
diagnosed post-mortem (by histology and culture), while
another 6% were diagnosed during the last 24 h before
death. Of note, in older series, rates of post-mortem diagno-
sis were much higher. In a series published by Pagano et al.
[21], ante-mortem diagnosis of zygomycosis was made in
54% of cases, while in another series of 185 cases of dissemi-
nated zygomycosis published by Ingram et al. [22], > 90%
were diagnosed at post-mortem examination. Methods for
diagnosis of zygomycosis varied from centre to centre (i.e.
molecular typing was not performed on all isolates). The
responsible pathogen was isolated in cultures in 172/230
(75%) cases. Similar rates have been reported by Roden et al.
[4]: a positive culture result was obtained in 50% of cases,
but there was a clear increase in culture positivity over time,
with 71% of all cases since 2000 diagnosed on the basis of
culture results. In another ﬁve cases the diagnosis was made
by tissue PCR. The use of PCR is an emerging method aiding
in the diagnosis of zygomycosis and, although it has several
limitations, can be an important diagnostic tool if no other
method is available, provided that the proper techniques are
selected [15,23]. The most commonly isolated pathogens in
the present study were Rhizopus spp., followed by Mucor
spp. and Lichtheimia corymbifera (formerly Absidia corymbifera).
Of note, Lichtheimia species reported in the present study
constituted 19% of all zygomycetes isolated, while in the
study by Roden et al. [4], the respective percentage was only
5%. This may be due either to an actual rise of these species,
to improved identiﬁcation of the fungus in recent years, to
geographic differences, or to bias in reporting.
Treatment of zygomycosis was medical and/or surgical.
Liposomal amphotericin B was the antifungal used in 68%
(130/192) of patients who received medical antifungal treat-
ment, while amphotericin B lipid complex was given to 4%
(7/192) of patients. In some countries amphotericin B deoxy-
cholate is still widely used, despite its toxicity. In this study
conventional amphotericin B was administered to 11% (21/
TABLE 5. Patients who received medical or surgical treat-
ment
Treatment
Number of
patients (%)a
Number of patients
who died (%)b
Medical and surgical 90 (40) 20/84 (24)
Only medical 102 (46) 49/85 (58)
Only surgical 9 (4) 4/9 (44)
None 24 (11) 21/22 (95)
Total number of medical treatments 192 (85) 69/169 (41)
Total number of surgical treatments 99 (44) 24/93 (26)
aData regarding treatment were missing in ﬁve cases. Percentages were calcu-
lated using 225 as the denominator.
bData regarding outcome were missing in 30 cases, so mortality was calculated
based on available data.
TABLE 6. Antifungal drugs administered as treatment for
zygomycosis
Medication Number (%)
Number of patients
who died (%)a
Amphotericin B aloneb 90 (39) 32/82 (39)
d-AmB 12/90 (13) 6/12 (50)
L-AmB 68/90 (76) 20/62 (32)
ABLC 4/90 (4) 2/4 (50)
Unspeciﬁed ampho B 6/90 (7) 4/4 (100)
Amphotericin B + posaconazoleb 48 (21) 13/43 (30)
Amphotericin B + Posa + otherc 13 (6) 2/11 (18)
Amphotericn B + otherc 16 (7) 11/16 (69)
Posaconazole alone 17 (7) 6/10 (60)
Otherd 8 (3) 3/6 (50)
None 33 (14) 26/31 (84)
Unknown 5 (2) 1/1 (100)
Total 230 94/200 (47)
aData regarding outcome were missing in 30 cases, so mortality was calculated
based on available data.
bPosaconazole was administered either in combination with (18 cases, 38%) or
sequentially following amphotericin B treatment (28/48 cases, 58%). In two cases
it was unclear whether they were given in combination or sequentially. The for-
mulation of amphotericin B used was liposomal amphotericin B in 43 cases
(90%).
cCaspofungin, itraconazole, voriconazole, ﬂuconazole.
dFluconazole, itraconazole, voriconazole, caspofungin. The three patients who
survived had all undergone surgery.
TABLE 4. Species of isolated zygomycetes. In another ﬁve
cases, the fungus did not grow in cultures but was diag-
nosed by tissue PCRa
Isolated fungi Number (%)
Rhizopus species 58 (34)
Not speciated 25
Rhizopus arrhizus (Rhizopus oryzae) 24
Rhizopus microsporus 7
Rhizopus microsporus var. rhizopodiformis 1
Rhizopus pusillus 1
Mucor species 33 (19)
Not speciated 31
Mucor circinelloides 2
Rhizomucor pusillus 5
Rhizomucor variabilis 4
Lichtheimia speciesb 32 (19)
Not speciated 5
Lichtheimia corymbifera 27
Cunninghamella species 8 (5)
Not speciated 3
Cunninghamella bertholletiae 5
Apophysomyces elegans 2 (1)
Saksenae species 1
Zygomycetes not speciﬁed 19 (11)
Total 172 (100)
aTwo cases of Lichtheimia corymbifera from brain tissue, one of Rhizopus oryzae
from sinus biopsy, one case of Rhizopus pusillus from lung tissue and one of Rhi-
zomucor from bronchial aspirate.
bOlder names Absidia and Mycocladus.
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192) of patients who were treated medically. No comparison
could be made between groups taking the various formula-
tions of amphotericin B, because the numbers were not large
enough and there were several confounding factors such as
different underlying diseases and sites of infection. Multiple
regression analysis showed that treatment with amphotericin
B in general, whether alone or in combination, signiﬁcantly
improved outcome. The other factors favouring a better out-
come were surgical treatment and trauma as an underlying
condition.
Administration of voriconazole before the diagnosis of
zygomycosis was found to be a risk factor for zygomycosis
on univariate but not on multivariate analysis. There have
been several reports suggesting that voriconazole use may
play a role in the increased occurrence of zygomycosis
[7,24]. It has also been postulated that exposure to vorico-
nazole may lead to increased virulence of zygomycetes
organisms [25]. Previous treatment with caspofungin was
shown to be related to an adverse outcome on multivariate
analysis. However, the conﬁdence interval was very large,
thus weakening the relevance of this observation. A possible
explanation for the relatively poor outcome of patients
receiving this antifungal prior to the diagnosis of zygomycosis
is that caspofungin was given empirically for a presumed fun-
gal infection, thus delaying the initiation of a drug with
potent in vitro activity against zygomycetes (amphotericin B).
A signiﬁcant number of patients developed breakthrough
zygomycosis while receiving prophylactic therapy with an
azole (40 received ﬂuconazole, 7 received itraconazole and 2
received posaconazole). In vitro studies have shown that
ﬂuconazole has no activity against the Mucorales. Itraconazole
may be active against some species [26–28], while posaco-
nazole demonstrates good in vitro activity against several
zygomycetes [28,29], whereas in vivo activity in animal mod-
els is species dependent [30] Breakthrough zygomycosis
while on prophylaxis with these drugs has been reported in
other studies [16,31,32]. These observations may signify
resistance of some species to these antifungals; another fac-
tor that must be taken into account is that both itraconazole
and posaconazole have problematic pharmacokinetics and
even if the administered dose is correct, the serum levels
may be suboptimal and therefore ineffective.
Total mortality in the present study was 47%, which is
higher than that reported in two recent series [17,21]. Com-
paring the various clinical presentations, patients with dis-
seminated disease had the highest mortality, followed by
patients with pulmonary disease. The best outcome was seen
in patients who were immunocompetent, of whom only one
of 18 died (6%). The underlying disease leading to the worst
prognosis was haematopoietic cell transplantation (mortality
76%), while patients with haematological malignancies and
diabetes mellitus had similar outcomes (mortality 52% and
55% respectively). However, in patients who had only diabe-
tes as an underlying disease, without any additional condi-
tions such as malignancies or trauma (Table 1), mortality was
44% (8/18).
In conclusion, this large European study found that zygo-
mycosis continues to be a disease with a dismal prognosis in
about half of the cases. Clinicians treating patients with dia-
betes, haematological malignancies or trauma, or patients
who are immunosuppressed for any reason, should have a
high index of suspicion for the disease and make every effort
TABLE 7. Factors related to outcome on univariate analysis
Outcome
Univariate analysis Multivariate analysis
Odds
ratio p 95% conﬁdence interval
Odds
ratio p 95% conﬁdence interval
Age 1.02 0.002 1.00921 1.040164 1.03 0.005 1.008854 1.051944
Soft tissue 0.30 0.02 0.1170924 0.8145019 0.13 0.019 0.0265983 0.7209237
Trauma 0.09 0.003 0.0215813 0.4525246 – – – –
Corticosteroids 2.15 0.008 1.223825 3.790619 – – – –
Prior antifungal 2.08 0.011 1.182969 3.681554 – – – –
Prior voriconazole 2.60 0.011 1.241533 5.452466 – – – –
Prior caspofungin 3.69 0.009 1.388624 9.809659 5.70 0.011 1.492133 21.82155
Prior azole 2.04 0.014 1.153278 3.624237 – – – –
Medical treatment 0.18 0.001 0.0731678 0.488193 – – – –
Treatment with amphotericin B alone 0.18 0.001 0.0661397 0.50083 0.14 0.006 0.036421 0.5659631
Treatment with amphotericin B and posaconazolea 0.14 0.001 0.0503203 0.4342687 0.09 0.003 0.0215417 0.442235
Treatment with amphotericin B and posaconazole
and other antifungalb
0.04 0.008 0.0043601 0.4335625 0.05 0.029 0.0046377 0.7538557
Surgical treatment 0.16 <0.001 0.086244 0.303416 0.21 <0.001 0.0913973 0.4832143
Variables entered into univariate analysis included age, sex, underlying diseases, treatment with corticosteroids prior to the diagnosis of zygomycosis, treatment with immuno-
suppressives prior to the diagnosis of zygomycosis, treatment with antifungals prior to the diagnosis of zygomycosis, sites of infection and types of treatment. Only the statis-
tically signiﬁcant are shown (p <0.05).
aPosaconazole was given either in combination with or sequentially following amphotericin B administration.
bPosaconazole and other drugs were given either in combination with or after amphotericin B administration.
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to obtain tissue for histology, culture and, if possible, PCR. A
combination of liposomal amphotericin B with surgery offers
the best chance of recovery.
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